Related Experiment Video
Updated: May 28, 2025

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Metabolite Profiling and Anti-Inflammatory Activities of Fritillaria cirrhosa D. Don Bulbs Derived from Tissue
Yu Wang1,2,3, Jiamin Liu1,2,3, Enhao Zhang1,2,4
1Natural Products Chem-Bio Innovation Center, Chengdu University, Chengdu 610106, China.
Abstract:
Fritillaria cirrhosa D. Don (known as Chuan-Bei-Mu in Chinese) is a prominent medicinal plant utilized in traditional medicine for chronic respiratory ailments. It has garnered global acknowledgment because of its incorporation in many herbal preparations, resulting in a significant increase in demand and, consequently, leading to the decimation of wild populations. The study aimed to obtain regenerated plantlets of F. cirrhosa using in vitro propagation techniques and evaluate the accumulation of active metabolites and anti-inflammatory properties from in vitro and natural plant bulbs. UHPLC-Q-TOF/MS analysis identified 267 metabolites. Notably, 118 metabolites showed significantly different intensities between the wild bulbs (WBs) and in vitro tissue culture-regenerated bulbs (RBs). Higher edpetiline amounts were obtained from the RBs, and 14 steroid-related metabolites were elevated in RBs. Both RB and WB extracts had comparable anti-inflammatory abilities and significantly inhibited TNF-α-induced epithelial cell TSLP release. Subsequent mechanistic studies revealed that the efficacy of WB and RB extracts depended on the regulation of the TRPV1/NFAT pathway. These findings highlight the viability of in vitro regeneration and medicinal part replacement as sustainable alternatives to the existing detrimental overharvesting of wild Chuan-Bei-Mu populations.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017